ANVIL: Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (clinicaltrials.gov) - Sep 30, 2026 - P3 | N=903 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ May 2027 | Trial primary completion date: Dec 2026 ➔ May 2027
Trial completion date • Trial primary completion date • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR
|